NANOMETICS LLC
Medtech
Fixed-dose combination topical cream containing calcipotriol and 5-fluorouracil (5-FU) for treating actinic keratosis
phdbiosciences.com →- Grants
- $14M
- 19 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 0 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A targeted immunomodulator for the treatment of acute sickle crisis | $224,901 | |
| Federal grant | Department of Health and Human Services · Phase II · Schiff base forming sunscreen filters for long-wear UV protection | $750,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · The Translational Development of a Therapeutic For Triple Negative Breast Cancer | $749,959 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · The Translational Development of a Therapeutic For Triple Negative Breast Cancer | $1,499,919 | |
| Federal grant | Department of Health and Human Services · Phase I · A targeted drug for the treatment of inflammation in cystic fibrosis lung disease | $224,958 | |
| Federal grant | Department of Health and Human Services · Phase I · A targeted drug for the treatment of inflammation in cystic fibrosis lung disease | $224,958 | |
| Federal grant | Department of Health and Human Services · Phase II · The Translational Development of a Therapeutic For Triple Negative Breast Cancer | $749,960 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome | $1,999,248 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome | $999,914 | |
| Federal grant | Department of Health and Human Services · Phase II · A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome | $1 | |
| Federal grant | Department of Health and Human Services · Phase I · A repurposed molecule as an oral therapeutic to improve vascular flow in sickle cell disease | $224,553 | |
| Federal grant | Department of Health and Human Services · Phase I · The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer | $224,831 | |
| Federal grant | Department of Health and Human Services · Phase II · A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome | $999,333 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel small molecule Bax activator as an oral therapeutic for the treatment of lung cancer. | $299,676 | |
| Federal grant | Department of Health and Human Services · Phase II · The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Furthering the clinical development of a first in class, water resistant sunscreen to meet emerging environmental regulations | $398,768 | |
| Federal grant | Department of Health and Human Services · Phase II · The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis | $1,000,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 703 | NOVA Thin Film Pharmaceuticals LLC | — | — |
| 704 | COMPUTER TECHNOLOGY ASSOCIATES, INC. | — | — |
| 705 | LIFESPAN TECHNOLOGIES LLC | — | — |
| 706 | NANOMETICS LLC | — | — |
| 707 | SAFELYYOU, INC. | — | — |
| 708 | APTAMATRIX, INC. | — | — |
| 709 | Smart Diagnostics Systems LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Pump Spray Or Pressurized Aerosol Device With Applicator Armapplication
- Pump Spray Or Pressurized Aerosol Device With Applicator Armapplication
- Pump Spray Or Pressurized Aerosol Device With Flexible Extension Applicatorapplication
- Mtap Inhibitors For The Treatment Of Sickle Cell Diseaseapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.